Citations

Clear

3042 citation(s) found for "Kumar, S".

Robust and efficient identification of biomarkers by classifying features on graphs
Hwang, Tae-Hyun, Sicotte, Hugues , Tian, Ze , Wu, Baolin , Kocher, Jean-Pierre, Wigle, Dennis A. , Kumar, Vipin , Kuang, Rui , Kocher, Jean-Pierre

Mayo Clinic

Bioinformatics | July 25, 2008 | Volume: 24 | Issue: 18 | Pages: 2023-2029

10.1093/bioinformatics/btn383 | PMID 18653521 Get It

AbstractMotivation: A central problem in biomarker discovery from large-scale gene expression or single nucleotide polymorphism (SNP) data is the computational challenge of taking into account the dependence among all the features. Methods that ignore the dependence usually identify non-reproducible biomarkers across independent datasets. We introduce a new graph-based semi-supervised feature classification algorithm to identify discriminative disease markers by learning on bipartite graphs. Our algorithm directly classifies the feature nodes in a bipartite graph as positive, negative or neutral with network propagation to capture the dependence among both samples and features (clinical and genetic variables) by exploring bi-cluster structures in a graph. Two features of our algorithm are: (1) our algorithm can find a global optimal labeling to capture the dependence among all the features and thus, generates highly reproducible results across independent microarray or other high-thoughput datasets, (2) our algorithm is capable of handling hundreds of thousands of features and thus, is particularly useful for biomarker identification from high-throughput gene expression and SNP data. In addition, although designed for classifying features, our algorithm can also simultaneously classify test samples for disease prognosis/diagnosis.Results: We applied the network propagation algorithm to study three large-scale breast cancer datasets. Our algorithm achieved competitive classification performance compared with SVMs and other baseline methods, and identified several markers with clinical or biological relevance with the disease. More importantly, our algorithm also identified highly reproducible marker genes and enriched functions from the independent datasets.Availability: Supplementary results and source code are available at http://compbio.cs.umn.edu/Feature_Class.Contact: kuang@cs.umn.eduSupplementary information: Supplementary data are available at Bioinformatics online.
P4‐300: Gene expression profiling to identify microvascular changes in Alzheimer's disease mouse models
Pereson, Sandra, Vandewoestyne, Mado, Broeck, Bianca Van, Cuijt, Ivy , Peeters, E.F.H.I., Ceuterick, Chantal, McGowan, Eileen , Jucker, Mathias , Broeckhoven, Christine Van , Deforce, Dieter L. D. , Kumar‐Singh, Samir

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_23 | Pages: No page available

10.1016/j.jalz.2008.05.2369 Get It

Comparison between Immunoturbidimetry, Size-Exclusion Chromatography, and LC-MS to Quantify Urinary Albumin
Shaikh, Aisha , Seegmiller, Jesse C. , Borland, Timothy M., Burns, Bradley E., Ladwig, Paula M. , Kumar, Rajiv , Larson, Timothy S., Singh, Ravinder J. , Lieske, John C. , Kumar, Rajiv

Mayo Clinic

Clinical Chemistry | July 11, 2008 | Volume: 54 | Issue: 9 | Pages: 1504-1510

10.1373/clinchem.2008.107508 | PMID 18617580 Get It

Abstract Background: The accurate and precise measurement of urinary albumin is critical, since even minor increases are diagnostically sensitive indicators of renal disease, cardiovascular events, and risk for death. To gain insights into potential measurement biases, we systematically compared urine albumin measurements performed by LC-MS, a clinically available immunoturbidimetric assay, and size-exclusion HPLC. Methods: We obtained unused clinical urine samples from 150 patients who were stratified by degrees of albuminuria (<20 mg/L, 20–250 mg/L, >250 mg/L) as determined by the immunoturbidimetric assay used in our clinical laboratory (Roche Hitachi 912). Urine albumin was then remeasured via LC-MS and HPLC (Accumin™) assays. Results: The immunoturbidimetric assay, calibrated using manufacturer-supplied serum-derived calibrators (Diasorin), underestimated albumin compared with LC-MS. After calibration with purified HSA, this immunoturbidimetric assay correlated well with LC-MS. HPLC overestimated albumin compared with both LC-MS and immunoturbidimetry. The current LC-MS and HPLC assays both performed poorly at concentrations <20 mg/L. Conclusions: Efforts are needed to establish gold-standard traceable calibrators for clinical assays. LC-MS is a specific method to quantify albumin in native urine when concentrations exceed 20 mg/L, and therefore could be employed for standardization among assays.
Progenitor Cell Therapy in a Porcine Acute Myocardial Infarction Model Induces Cardiac Hypertrophy, Mediated by Paracrine Secretion of Cardiotrophic Factors Including TGFβ1
Doyle, Brendan, Sorajja, Paul , Hynes, Brian, Kumar, Arun , Araoz, Phillip A., Stalboerger, Paul G., Miller, Dylan V. , Reed, Cynthia , Schmeckpeper, Jeffrey , Wang, Shaohua , Liu, Chunsheng , Krüger, David , Riederer, Stephen J. , Caplice, Noel M. , Sorajja, Paul , Terzic, André

Mayo Clinic

Stem Cells and Development | June 18, 2008 | Volume: 17 | Issue: 5 | Pages: 941-952

10.1089/scd.2007.0214 | PMID 18564032 Get It

Proteasome β Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics
Wang, Liewei , Kumar, Shaji , Kalari, Krishna R. , Moon, Irene, Pelleymounter, Linda L., Batzler, Anthony , Eckloff, Bruce W., Wieben, Eric D. , Greipp, Philip R., Fridley, Brooke L. , Hildebrandt, Michelle A.T. , Kalari, Krishna R

Mayo Clinic

Clinical Cancer Research | June 2, 2008 | Volume: 14 | Issue: 11 | Pages: 3503-3513

10.1158/1078-0432.ccr-07-5150 | PMID 18519783 Get It

Abstract Purpose: The proteasome is a multisubunit cellular organelle that functions as a nonlysosomal threonine protease. Proteasomes play a critical role in the degradation of proteins, regulating a variety of cellular processes, and they are also the target for antineoplastic proteasome inhibitors. Genetic variation in proteasome subunits could influence both proteasome function and response to drug therapy. Experimental Design: We resequenced genes encoding the three active proteasome β subunits using 240 DNA samples from four ethnic groups and the β5 subunit gene in 79 DNA samples from multiple myeloma patients who had been treated with the proteasome inhibitor bortezomib. Resequencing was followed by functional studies of polymorphisms identified in the coding region and 3′-flanking region (3′-FR) of PSMB5, the gene encoding the target for clinically useful proteasome inhibitors. Results: Resequencing of 240 DNA samples identified a series of novel ethnic-specific polymorphisms that are not represented in public databases. The PSMB5 3′-FR 1042 G allele significantly increased transcription during reporter gene studies, observations confirmed by genotype-phenotype correlations between single nucleotide polymorphisms (SNP) in PSMB5 and mRNA expression in the 240 lymphoblastoid cell lines from which the resequenced DNA was obtained. Studies with patient DNA samples identified additional novel PSMB5 polymorphisms, including a SNP and an insertion in the 3′-FR. Reporter-gene studies indicated that these two novel polymorphisms might decrease transcription. Conclusions: These results show that nonsynonymous coding SNPs in the PSMB5 gene did not show significant effects on proteasome activity, but SNPs did influence transcription. Future studies might focus on regulatory region polymorphisms.
Pharmacoangiographic Evidence of the Presence and Anatomical Dominance of Accessory Pudendal Artery(s)
Nehra, Ajay, Kumar, Rajeev , Ramakumar, Sanjay, Myers, Robert P., Blute, Michael L., McKusick, Michael A.

Mayo Clinic

Journal of Urology | April 19, 2008 | Volume: 179 | Issue: 6 | Pages: 2317-2320

10.1016/j.juro.2008.01.117 | PMID 18423744 Get It

Expression and Regulation of the Vitamin D Receptor in the Zebrafish, Danio rerio
Craig, Theodore A., Sommer, Stacy, Grande, Joseph P. , Kumar, Rajiv , Sussman, Caroline R. , Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | April 14, 2008 | Volume: 23 | Issue: 9 | Pages: 1486-1496

10.1359/jbmr.080403 | PMID 18410235 Get It

Abstract Vitamin D and vitamin D metabolites such as 25-hydroxyvitamin D and 1α,25-dihydroxyvitamin D [1α,25(OH)2D3] circulate in the serum of fish. The receptor for 1α,25(OH)2D3 (VDR) has previously been cloned from fish intestine, and ligand binding assays have shown the presence of the VDR in the gills, intestine, and liver of fish. Using immunohistochemical methods with specific antibodies against the VDR, we now report that the VDR is widely expressed in tissues of the adult male and female zebrafish, Danio rerio, specifically in epithelial cells of gills, tubular cells of the kidney, and absorptive cells in the intestine. Additionally, the VDR is expressed in the skin, the olfactory organ, the retina, brain, and spinal cord. Sertoli cells of the testis, oocytes, acinar cells of the pancreas, hepatocytes, and bile duct epithelial cells express substantial amounts of the receptor. Osteoblast-like cells and chondrocytes also express VDR. Preimmune serum and antiserum preadsorbed with Danio VDR protein fails to detect VDR in the same tissues. The VDR is also present in the developing eye, brain, and otic vesicle of 48- and 96-h postfertilization zebrafish embryos. Parenteral administration of 1α,25(OH)2D3 increases concentrations of VDR in intestinal epithelial cells but not in epithelial cells of the gills. Lithocholic acid, however, does not alter concentrations of VDR after parenteral administration. The data suggest that VDR is widely distributed in tissues of the zebrafish, D. rerio, and is likely to play important roles in epithelial transport, bone, and endocrine function. Furthermore, concentrations of the receptor seem to be regulated by its ligand, 1α,25-dihydroxyvitamin D but not by lithocholic acid. Zebrafish may serve as a useful model in which to assess the function of the VDR in diverse tissues.
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, Shaji , Rajkumar, S. Vincent , Dispenzieri, Angela , Lacy, Martha Q. , Hayman, Suzanne R. , Zeldenrust, Steven R., Dingli, David , Lust, John A., Greipp, Philip R., Kyle, Robert A. , Buadi, Francis K. , Russell, Stephen J. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | November 2, 2007 | Volume: 111 | Issue: 5 | Pages: 2516-2520

10.1182/blood-2007-10-116129 | PMID 17975015 Get It

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem-cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P < .001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P < .001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.
Relationship Between Depth of Response and Outcome in Multiple Myeloma
Dingli, David , Pacheco, Jorge M. , Nowakowski, Grzegorz S. , Kumar, Shaji , Dispenzieri, Angela , Hayman, Suzanne R. , Lacy, Martha Q. , Gastineau, Dennis A., Gertz, Morie A. , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Journal of Clinical Oncology | October 30, 2007 | Volume: 25 | Issue: 31 | Pages: 4933-4937

10.1200/jco.2007.11.7879 | PMID 17971591 Get It

Purpose High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patients with multiple myeloma, partly because of higher complete response (CR) rates. Some studies suggest that tandem transplantation gives superior results. The aim of this study was to determine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression (TTP) and overall survival (OS). We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS. Patients and Methods All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified. The characteristics and long-term outcome of these patients were evaluated. Results We identified 14 patients with BCR and 103 patients with ACR who were treated in similar fashion. The patients have been followed for more than 6 years, and the median for OS has not been reached (60-month survival, 55% for BCR and 63% for ACR; P = .83). The median TTP was 43 months for BCR and 34 months for ACR (P = .39). Conclusion The depth of the response in myeloma does not necessarily lead to an improvement in TTP and OS. Tumor dynamics considerations show that the yield from sequential cycles of chemotherapy decreases. Patients who achieve CR with the first transplant can be safely observed without jeopardizing OS.
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Dispenzieri, Angela , Kyle, Robert A. , Katzmann, Jerry A., Therneau, Terry M. , Benson, Joanne, Clark, Raynell, Melton, L. Joseph, Kumar, Shaji , Fonseca, Rafaël , Jelinek, Diane F., Rajkumar, S. Vincent , Larson, Dirk R. , Benson, Joanne T., Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | October 17, 2007 | Volume: 111 | Issue: 2 | Pages: 785-789

10.1182/blood-2007-08-108357 | PMID 17942755 Get It

We hypothesized that increased monoclonal free kappa or lambda immunoglobulin light chains in smoldering multiple myeloma (SMM), as detected by the serum free light chain (FLC) assay, indicates an increased risk of progression to active myeloma. Baseline serum samples obtained within 30 days of diagnosis were available in 273 patients with SMM seen from 1970 to 1995. At a median follow-up of surviving patients of 12.4 years, transformation to active disease has occurred in 59%. The best breakpoint for predicting risk of progression was an FLC ratio of 0.125 or less, or 8 or more (hazard ratio, 2.3; 95% CI, 1.6-3.2). The extent of abnormality of FLC ratio was independent of SMM risk categories defined by number of bone marrow plasma cells (BMPCs) and size of serum M proteins (BMPC ≥ 10% and serum M protein ≥ 3 g/dL; BMPC ≥ 10% but serum M protein < 3 g/dL; and serum M protein≥ 3 g/dL but BMPC < 10%). Incorporating the FLC ratio into the risk model, the 5-year progression rates in high-, intermediate-, and low-risk groups were 76%, 51%, and 25%, respectively. The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM.